Study results by Moreland, et al comparing febuxostat with allopurinol in Patients with hyperuricemia and gout are now published (N Engl J Med 353: 2505-2507). In this multicenter study, 760 patients received either febuxostat (80mg or 120mg) or allopurinol (300mg). 53% and 62% of patients receiving 80mg and 120mg, respectively, achieved serum urate concentration levels of less than 360 mmol perliter compared to 21% of patients receiving allopurinol. These data were previously reported at the 2004 American Rheumatology meeting.
Arthritis Center
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.
